DNA topoisomerase and antitumor

Chinese Pharmacological Bulletin

Volumn 23, Issue 1, 2007, Pages 20-23

  Mo, Xiao Mei ^a   Li, Jing ^a   Geng, Mei Yu ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Antitumor; atMDR; DNA topoisomerase

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG MECHANISM; ENZYME INHIBITION; PROTEIN FUNCTION;

EID: 34247510736     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Tian L, Claeboe C D, Hecht S M, et al. Guarding the genome: Electrostatic repulsion of water by DNA suppresses a potent nuclease activity of topoisomerase I [J]. Mol Cell, 2003, 12 (1): 199-208.
2. Strahs D, Zhu C X, Cheng B. Experimental and computational investigations of Ser10 and Lys13 in the binding and cleavage of DNA substrates by Escherichia coli DNA topoisomerase I [J]. Nucleic Acids Res, 2006, 34(6): 1785-97.
3. Corbett K D, Berger J M, Structure, molecular mechanisms and evoluionary relationships in DNA topoisomeras[J]. Annu Rev Biophys Biomol Struct, 2004,33:95-118.
4. Van Duyne G D. A structural view of Cre-loxP site-specific recombination[J]. Annu Rev Biophys Biomol Struct, 2001,30:87-104.
5. Hansen G, Harrenga A, Wieland B. Crystal structure of full length topoisomerase I from thermotoga maritime[J]. J Mol Biol, 2006,358(5): 1328-40.
6. Tinari N, Lattanzio R, Natoli C. Changes of topoisomerase II alpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival[J]. Clin Cancer Res, 2006,12(5): 1501-6.
7. Tretiakova M, Turkyilmaz M, Grushko T. Topoisomerase II alpha in Wilms tumors: gene alterations and immuno expression[J]. J Clin Pathol, 2006, 23(Epub ahead of print).
8. Vokes E E, Gordon G S, Rudin C M, et al. A phasell trial of 9-aminocamptothecin(9-AC) as a 120-h infusion in patients with nonsmait cell lung cancer[J]. Inves New Drugs, 2002,19(4): 29-33.
9. Song G Y, Kim Y, Zheng X G, et al. Naphthazarin derivatives (IV): synthesis, inhibition of DNA topoisomerase I and cytotoxicity or 2-or 6-acy-5, 8-dimethoxy-1,4-naphthoquinones[J]. Eur J Med Chem, 2000,35(3): 291-8.
10. Yang F, Chen Y, Duan W. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor[J]. Int J Cancer, 2006,119(5): 1184-93.
11. De Jonge M J, Kaye S, Verweij J. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours[J]. Br J Cancer, 2004,91(8): 1459-65.
12. Kruczynski A, Barret J M, Van Hille B. Decreased nucleotide excision repair activity and alterations of topoisomerase II alpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II[J]. Clin Cancer Res, 2004,10(9): 3156-68.
13. Dittrich C, Dieras V, Kerbrat P. Phase II study of XR5 000(DA-CA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer[J]. Invest New Drugs, 2003,21(3): 347-52.
14. Jensen L H, Dejligbjerg M, Hansen L T, et al. Characterisation of DNA damage and cytotoxicity induced by the bisdioxopiperazine anti-cancer agent ICRF-187(dexrazoxane)in yeast and mammalian ceils[J]. BMC Pharmacol, 2004, 4(1): 31-49.
15. Liu M H, Qing C, Liu J K, et al. Study on the antitumor activity of Albaconol and its effect on DNA topoisomerase II [J]. Chin Pharmacol Bull, 2004, 20(11): 1224-8.
16. Yamada M, Hayashi K, Hayashi H. Nepalensinols D-G, new resveratrol oligomers from Kobresia nepalensis(Cyperaceae) as potent inhibitors of DNA topoisomerase II [J]. Chem Pharm Bull (Tokyo), 2006, 54(3): 354-8.
17. Miyata S, Wang L Y, Yoshida C. Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor[J]. Bioorg Med Chem, 2006, 14(6): 2048-51.
18. Wada S, Tanaka R. Synthetic lanostane-type triterpenoids as inhibitors of DNA topoisomerase II [J]. Bioorg Med Chem Lett, 2005,15(12): 2966-9.
19. Gilroy K L, Leontiou C, Padget K, et al. mAMSA resistant human topoisomerase II beta mutation G465D has reduced ATP hydrolysis activity[J]. Nucleic Acids Res, 2006, 34(5): 1597-607.
20. Matsumoto Y, Tamiya T, Nagao S. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2 [J]. J Med Invest, 2005, 52(1 -2): 41-8.
21. Yasui K, Mihara S, Zhao C, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance[J]. Cancer Res, 2004,64(4): 1403-10.
22. Arakawa Y, Suzuki H, Saito S. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells[J]. Mol Cancer Ther, 2006,5(3): 502-8.